<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) patients </plain></SENT>
<SENT sid="1" pm="."><plain>After a 5-week induction phase of weekly infusions consisting of <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) plus leukovorin rescue, and intrathecal MTX or <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ARA-C), a consolidation phase including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> ARA-C plus <z:chebi fb="2" ids="27899">cisplatin</z:chebi> was given </plain></SENT>
<SENT sid="2" pm="."><plain>Responding patients achieving less than complete response (CR) after completion of the initial induction phase, were promptly shifted to a high-dose, stem cell supported sequential chemotherapy schema (R-HDS) </plain></SENT>
<SENT sid="3" pm="."><plain>Patient characteristics: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH &gt; or = 460 U/l, 11 patients </plain></SENT>
<SENT sid="4" pm="."><plain>The median duration of the chemotherapy programme was 62 d (range, 43-94 d) </plain></SENT>
<SENT sid="5" pm="."><plain>Seventeen patients achieved a CR (77%), one patient died of progressive disease and four partial responders following induction were converted to CR following R-HDS </plain></SENT>
<SENT sid="6" pm="."><plain>Of 17 patients in CR, one died of infectious toxicity while in CR, and one relapsed at 30 months and died of progressive disease </plain></SENT>
<SENT sid="7" pm="."><plain>After a median follow-up of 28.7 months (range, 6-158 months), 16 patients (73%) were in continued CR </plain></SENT>
<SENT sid="8" pm="."><plain>Overall survival and progression-free survival were 77% [95% confidence interval (CI), 52-99%] and 68% (95% CI, 43-99%) respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Confirmation of these excellent efficacy and feasibility results by larger, multicentre and prospective studies is warranted </plain></SENT>
</text></document>